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The triggering receptor expressed on myeloid cells (TREM) family of proteins are
cell surface receptors with important roles in regulation of myeloid cell inflammatory
activity. In the central nervous system, TREM2 is implicated in further roles in microglial
homeostasis, neuroinflammation and neurodegeneration. Different TREM receptors
appear to have contrasting roles in controlling myeloid immune activity therefore the
relative and co-ordinated regulation of their expression is important to understand but is
currently poorly understood. We sought to determine how microglial TREM expression
is affected under neuroinflammatory conditions in vitro and in vivo. Our data show that
microglial Trem1 and Trem2 gene expression are regulated in an opposing manner by
lipopolysaccharide (LPS) in vitro in both adult murine and human microglia. LPS caused
a significant induction of Trem1 and a contrasting suppression of Trem2 expression. We
also observed similar divergent Trem1 and Trem2 responses in vivo in response to acute
brain inflammation and acute cerebral ischaemia. Our data show that inhibition of NF-κB
activation prevents the LPS-induced alterations in both Trem1 and Trem2 expression in
vitro indicating NF-κB as a common signaling intermediate controlling these divergent
responses. Distinct patterns of microglial Trem1 induction and Trem2 suppression to
different Toll-like receptor (TLR) ligands were also evident, notably with Trem1 induction
restricted to those ligands activating TLRs signaling via TRIF. Our data show co-ordinated
but divergent regulation of microglial TREM receptor expression with a central role for
NF-κB. Neuroinflammatory conditions that alter the balance in TREM expression could
therefore be an important influence on microglial inflammatory and homeostatic activity
with implications for neuroinflammatory and neurodegenerative disease.
Keywords: microglia, neuroinflammation, myeloid cells, NF-κB, TREM2, lipopolysaccharide (LPS), microglial
activation
INTRODUCTION
The triggering receptor expressed on myeloid cells (TREM) family of proteins comprises a group
of cell surface innate immune receptors of the immunoglobulin superfamily that are expressed on
various myeloid cell populations throughout the body, including microglia in the brain (Colonna,
2003; Colonna and Wang, 2016). The TREM gene cluster, located on human chromosome 6 and
mouse chromosome 17, includes genes encoding TREM1 and TREM2 (human and mouse), and
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TREM3 (mouse only). The TREM-like genes, Treml1 and Treml2
which encode the proteins TREM-like transcript-1 (TLT-1)
and TLT-2 also form part of this cluster. TREM proteins are
structurally related, containing a single extracellular variable-
type immunoglobulin domain and a transmembrane domain
incorporating a charged lysine residue enabling association
with the adaptor protein DAP12 that is obligatory for signal
transduction (Klesney-Tait et al., 2006). Growing evidence
supports a role for TREMs in the regulation of innate immune
responses in various tissues, including the CNS (Sharif and
Knapp, 2008). Moreover, despite sharing the requirement for
signaling through DAP12 and its ITAM motif, it is becoming
clear that TREM1 and TREM2 can have contrasting effects on
immune regulation (Sharif and Knapp, 2008). Whereas TREM1,
largely studied outside the CNS, has been shown to amplify
inflammation in a number of models (Bouchon et al., 2000, 2001;
Netea et al., 2006; Hommes et al., 2014, 2015), TREM2 appears to
restrain myeloid cell responses to various inflammatory stimuli
(Hamerman et al., 2006; Turnbull et al., 2006; Ito andHamerman,
2012). Accordingly, the balance in signaling through these
receptors is likely important for influencing the strength of innate
immune activity.
The importance of TREM function in the CNS was first
highlighted by the discovery of Nasu-Hakola disease, also known
as Polycystic Lipomembranous Osteodysplasia with Sclerosing
Leukoencephalopathy (PLOSL) (Hakola, 1972; Nasu et al., 1973).
This is a fatal presenile dementia, also presenting with bone
pathology, caused by homozygous loss of function mutations
in TREM2 (or DAP12) affecting the microglial and ostecoclast
myeloid lineages (Paloneva et al., 2000, 2001, 2002). Recent
studies have also revealed that homozygous TREM2 mutations
cause a frontotemporal dementia-like syndrome in the absence
of bone pathology (Giraldo et al., 2013; Guerreiro et al., 2013a; Le
Ber et al., 2014). Moreover, TREM2mutations are associated with
an increased risk of developing Alzheimer’s disease (Guerreiro
et al., 2013b; Jonsson et al., 2013), frontotemporal dementia
(Thelen et al., 2014) and amyotrophic lateral sclerosis (Cady
et al., 2014). Studies using animal models of neurodegeneration
have also suggested disease-modifying effects of TREM2 (Piccio
et al., 2007; Jiang et al., 2014; Jay et al., 2015; Wang et al., 2015).
Mechanisms underlying TREM2-linked neurodegeneration are
unclear but may involve impaired intracellular trafficking of
TREM2 and deficiencies in microglial phagocytosis, reactivity
and neuro-immune regulation (Colonna and Wang, 2016).
Regulation of TREM gene and protein expression will
influence the extent and balance of signaling through these
receptors and may be important for their effects on inflammation
and disease. Elevated TREM2 gene or protein expression has
been reported in animal models of chronic neurodegeneration
(Jay et al., 2015; Wang et al., 2015) and in human post-mortem
AD tissue (Lue et al., 2015), although the extent to which this
simply reflects the marked proliferation of microglia that occurs
in these conditions is unknown. In contrast, there is negligible
data on TREM1 expression in the CNS. TREM1 is expressed
on myeloid cells outside the brain including neutrophils,
monocytes, macrophages and dendritic cells (Sharif and Knapp,
2008). Stimulation of macrophages with Toll-like receptor
(TLR) ligands caused contrasting changes in TREM1 (increased)
(Bouchon et al., 2001; Murakami et al., 2007; Zeng et al., 2007)
and TREM2 (decreased) (Turnbull et al., 2006) expression.
However, the coordinated regulation of TREM1 and TREM2
expression inmicroglia under neuroinflammatory conditions has
not been studied previously. Furthermore, although signaling
pathways triggered by TREM1 or TREM2 receptor binding have
been described (Arts et al., 2013; Colonna and Wang, 2016), the
intracellular mediators influencing transcriptional regulation of
TREM genes are not well understood, particularly in microglia.
In the present study, we sought to determine the comparative
regulation of TREM receptor expression in response tomicroglial
activation and the signaling mechanisms involved. We show that
microglial TREM1 and TREM2 expression is regulated in an
opposing manner in vitro and in vivo and that NF-κB activation
is a common intermediate governing this divergent regulation.
MATERIALS AND METHODS
Mining of Microarray Datasets for Trem
Analysis
To assess microglial Trem family expression at baseline in the
adult mouse brain, we mined expression data for selected genes
from microarray datasets we generated previously from purified
microglia or mixed cell brain homogenates (Grabert et al., 2016).
Datasets are publicly accessible at the NCBI gene Expression
Omnibus (GEO) with accession code GSE62420 (http://www.
ncbi.nlm.nih.gov/geo/GSE62420).
Mice
Male 8–12 week old mice (C57BL/6J, Charles River Laboratories)
were used in all experiments. Mice were maintained under
specific pathogen-free conditions and a standard 12 h light/ dark
cycle with unrestricted access to food and water. Mice were
housed in individually ventilated cages in groups of up to five
mice and were acclimatized for a minimum of 1 week prior to
procedures. All procedures involving live animals were carried
out under the authority of a UK Home Office Project License in
accordance with the “Animals (Scientific Procedures) Act 1986”
and Directive 2010/63/EU and were approved by The Roslin
Institute’s Animal Welfare and Ethics Committee.
Adult Mouse Microglial Isolation and
Culture
Microglia were isolated and cultured as described previously
(Grabert et al., 2016). Briefly, mice were perfused transcardially
with saline and the brain finely minced by scalpel blade in
ice-cold Hanks Balanced Salt Solution HBSS (Sigma-Aldrich),
centrifuged (400 g, 5min, 4◦C) resuspended and incubated for
1 h at 37◦C in digestion cocktail (50U/ml collagenase, 8.5U/ml
dispase, 100 ug/ml Nα-Tosyl-L-lysine chloromethyl ketone
hydrochloride, 5U/ml DNaseI in HBSS). Tissue was dissociated
using a Dounce homogeniser and the enzymatic reaction
terminated by addition of equal volume HBSS containing 10%
fetal bovine serum. Homogenates were centrifuged (400 g, 5min,
4◦C) and pellets resuspended in 35% Percoll (GE Healthcare,
Sweden), overlaid with HBSS then centrifuged (800 g, 45min,
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4◦C). The cell pellet enriched with microglia was resuspended
in separation buffer (0.5% bovine serum albumin, 2mM
EDTA in PBS). The cell suspension was incubated with anti-
CD11b microbeads (Miltenyi Biotec, UK) for 15min at 4◦C
then applied to a magnetic LS column (Miltenyi Biotec) and
cells retained on the column (microglia) were flushed. The
microglial suspension was centrifuged (400 g, 5min, 4◦C) and
resuspended in DMEM/F12 (Invitrogen) containing 10% FBS
and 1% penicillin/streptomycin. Cells were seeded in wells pre-
coated with poly-L-lysine at a density of 2 × 105 cells/ml and
cultured at 37◦C in a humidified incubator under 5% CO2.
Media was replaced after 48 h in culture and cell stimulations
performed after 72 h in culture by which time cells developed a
more ramifiedmorphology characteristic of microglia. Cells were
stimulated for 24 h with LPS (1 µg/ml), IL-4 (20 ng/ml) or DPBS.
BV2 Microglia Culture
Although there are limitations of using any cell line, the utility
of immortalized BV2 microglia as a suitable substitute for
primary microglia has been shown (Henn et al., 2009). BV2
cells were cultured in DMEM (Invitrogen) supplemented with
5% fetal bovine serum and 1% penicillin/streptomycin at 37◦C
in a humidified incubator under 5% CO2. Cells were seeded
at a density of 2.5 × 105 cells/ml 24 h before stimulations at
which point cells were >90% confluent. Prior to stimulation,
cells were washed twice with DPBS (Invitrogen) and cultured
in serum-free DMEM for at least 1 h. Cells were stimulated
for 24 h with one of the following: LPS (E. coli 0127:B8 1
µg/ml; Sigma-Aldrich); recombinant mouse IL-4 (20 ng/ml;
R&D Systems); Pam3CSK4 (5 µg/ml; Invivogen); polyinosinic-
polycytidylic acid (poly(I:C)) (50 µg/ml; Sigma-Aldrich); CpG
oligodeoxynucleotides (CpG ODN) (1 µM; Enzo Life Sciences);
or DPBS. In certain experiments, cells were pre-incubated with
inhibitors (Merck Millipore) of IκB kinase (BMS-345541, 1 or 10
µM), PI3 kinase (LY294002, 10 µM), ERK1/2 kinase (MEK1/2)
(PD98059, 10 µM), p38 MAP kinase (SB203580, 10 µM), c-Jun
N-terminal kinase (SP600125, 20 µM) or equivalent volume of
DMSO for 30min prior to LPS stimulation.
Human Microglial Isolation and Culture
Human microglia were isolated from adult brain tissue using
previously described protocols (Durafourt et al., 2013) under
ethical approval by the McGill University Health Center
Research Ethics Board (protocol ANTJ2001/1). Briefly, normal
appearing cortical tissue was resected from pharmacologically
intractable non-malignant cases of temporal lobe epilepsy.
Tissue was cleaned extensively and mechanically dissociated. A
single cell suspension was generated following gentle enzymatic
digestion using trypsin and DNAse prior to passing through
a nylon mesh filter. Single cell suspension underwent a Ficoll
ultracentrifugation step to remove myelin. Dissociated cells were
centrifuged, counted, and plated at 2 × 106 cells/mL in MEM
supplemented with 5% FBS, 0.1% penicillin/streptomycin and
0.1% glutamine. Microglia were grown for 3 days, collected and
plated at 1 × 105 cells/mL and maintained in culture for 6 d
during which time cells were left untreated or stimulated. Cells
were treated with IFN-γ (20 ng/ml) for 1 h followed by a 48 h
treatment with LPS (E coli 0127:B8, 100 ng/ml) or with IL-4
(20 ng/ml) and IL-13 (20 ng/ml) together for 48 h.
Human Microglial Gene Expression
Analysis
Microglia gene expression profiles was measured using a Human
Gene ST 2.0 Microarray Chip (Affymetrix). Raw intensity data
files were normalized using the Robust Multichip Average
(RMA) algorithm, averaged with Tukey’s bi-weight average
algorithm, and transformed to the log2 scale using the Affymetrix
Expression Console. Data was exported from Expression Console
into Affymetrix TranscriptomeAnalysis Console (TAC) software.
GraphPad Prism 5 was used to perform statistical analyses
(ANOVA and Bonferroni’s multiple comparison Test) and plot
individual gene expression. Data are expressed as Tukey’s bi-
weight average± SD. The dataset is publicly accessible in NCBI’s
GEO with accession number GSE76737 (https://www.ncbi.nlm.
nih.gov/geo/GSE76737).
Intracerebral Inflammation Model
Mice were positioned in a stereotaxic frame (Stoelting, USA)
under isoflurane anesthesia (with 0.2 L/min O2 and 0.5 L/min
N2O). The skull was exposed via a midline incision and a small
craniotomy was made overlying the left hemisphere 2mm lateral
to Bregma using an Ideal micro drill (tip diameter 0.8mm)
(Stoelting). Stereotaxic injections were performed using pre-
calibrated glass microcapillary pipettes (Drummond Scientific,
USA), previously pulled using a vertical electrode puller (Model
PP830, Japan). Co-ordinates for intrastriatal injection were 2
mm lateral to Bregma (left hemisphere) and 2.5mm below
the brain surface (Franklin and Paxinos, 2007). One microliter
LPS (E. coli 0127:B8, 5 mg/ml) or PBS was injected at a
rate of 0.5 µL/min. The wound was sutured and topical local
anaesthetic (EMLA lidocaine/prilocaine) applied. Mice were
recovered for 24 h.
Middle Cerebral Artery Occlusion
Experimental Stroke Model
Middle cerebral artery occlusion (MCAO) was performed under
isoflurane anesthesia (with 0.2 L/min O2 and 0.5 L/min N2O)
by insertion of a 6-0 nylon monofilament with a 2mm coated
tip (210 µm diameter; Doccol, USA) through the external
carotid artery and advanced through the internal carotid
artery to occlude the middle cerebral artery (MCA). The
filament was withdrawn after 40min to allow reperfusion, the
neck wound sutured and the animals recovered. Topical local
anaesthetic (EMLA lidocaine/prilocaine) was applied to the
wound. For sham surgery, the filament was advanced to theMCA
and immediately retracted. Sham-operated animals remained
anaesthetized for 40min and recovered as above. Core body
temperature was maintained at 37 ± 0.5◦C throughout the
procedure with a feedback controlled heating blanket (Harvard
Apparatus, UK). Mice were recovered for 24 h.
Brain Cell Suspension Preparation
24 h after intracerebral LPS injection or MCAO, mice were
perfused transcardially under isoflurane anesthesia as above
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with DEPC-treated (0.1%) saline to remove blood and the
hemisphere ipsilateral to intracerebral injection or MCAO was
dissected. Brain cell suspensions were prepared as above for
microglial isolation except after Percoll centrifugation cell pellets
were resuspended in FACS buffer for immediate flow cytometry
staining or in RNAprotect Cell Reagent (Qiagen) for storage at
−80◦C.
RNA Extraction and cDNA Synthesis
For RNA extractions from BV2 cells and isolated adult mouse
microglia, media was removed and cells incubated with Trizol
for 2 min at room temperature and mixed by pipetting then
incubated for a further 5min. For brain cell suspensions prepared
after intracerebral inflammation and stored in RNAprotect Cell
Reagent (Qiagen), cell suspensions were thawed and centrifuged
(5,000 g, 5min, 4◦C). The supernatant was discarded and the
cell pellet incubated with Trizol as above. Lysates were incubated
with 1-bromo-3-chloropropane (BCP) for 2min and centrifuged
(12,000 g, 5min, 4◦C) then the upper aqueous phase was removed
and the previous step repeated. The aqueous phase was then
incubated with 1 µl co-precipitant linear acrylamide and 250 µl
isopropanol before centrifugation (12,000 g, 10min, 4◦C). The
supernatant was removed and the RNA pellet washed in 75%
ethanol. The RNA suspension was then centrifuged (7,500 g,
5min, 4◦C), air-dried and resuspended in DNase/RNase-free
water. For brain homogenates prepared after MCAO, RNA
was extracted using the RNEasy Mini Kit (Qiagen) according
to manufacturer’s instructions. DNase treatment of all RNA
samples was performed using the DNA-free kit (Ambion)
according to manufacturer’s instructions. Concentration of
RNA samples was determined by Nanodrop 1000 (Thermo
Fisher Scientific) measurement. cDNA was synthesized from
DNase-treated RNA samples using Superscript III Reverse
Transcriptase (Life Technologies) according to manufacturer’s
instructions.
Quantitative PCR
Primers were designed using Primer BLAST (http://www.
ncbi.nlm.nih.gov/tools/primer-blast/) and validated to ensure
adequate efficiencies. Primer sequences were as follows: Arg1
forward 5′-GGAGACCACAGTCTGGCAGTTGGA-3′; Arg1
reverse 5′-GGACACAGGTTGCCCATGCAGA-3′; Gapdh




CTGGTGGTGACCAAGGGTTC; Trem1 reverse CTTGGG
TAGGGATCGGGTTG; Trem2 forward 5′-CTGCTGATCA
CAGCCCTGTCCCAA-3′; Trem2 reverse 5′-CCCCCAGTGC
TTCAAGGCGTCATA-3′; Gapdh was used as the housekeeping
gene. cDNA was mixed with forward and reverse primers, ROX
reference dye and Platinum SYBR Green qPCR Supermix-
UDG in DNase/RNase-free water and qPCR cycles performed
on a Stratagene Mx3005P thermocycler (Agilent) as follows:
hot-start denaturation cycle 95◦C for 10min, 40 cycles of
amplification at 95◦C for 15 s, 60◦C for 20 s and 72◦C for
1min, followed by one cycle of 95◦C for 1min, 55◦C for
30 s and 95◦C for 30 s. Cycle threshold (Ct) values of target
genes were normalized to Gapdh and data are expressed as
fold change relative to control group using the 2∧11Ct
method.
Flow Cytometry
Media was removed from cultured BV2 cells and cells washed
with DPBS then detached by incubation with trypsin for 30 s
at 37◦C. DMEM was added to neutralize trypsin and samples
were centrifuged (400 g, 5min) then pellets resuspended in
FACS buffer (DPBS containing 0.1% low endotoxin BSA).
Cell suspensions were added to a 96-well plate and low
affinity Fc receptors blocked by incubation of cells with anti-
CD16/32 antibody for 30min. Plates were centrifuged (400 g,
5min), supernatants discarded and cell pellets disrupted by
gentle agitation of plates. Cells were incubated with the
following fluorochrome-conjugated rat monoclonal antibodies
for 30 min: anti-mouse F4/80-PerCP (clone BM8, 1 µg/ml,
BioLegend); anti-mouse/human CD11b-APC-Cy7 (cloneM1/70,
1 µg/ml, BioLegend); anti-mouse TREM2-FITC (clone 78.18,
1 µg/ml, Abd Serotec); anti-mouse TREM1-Alexa Fluor 647
(clone L5-B8.2A12.3A12, 5 µg/ml, Abd Serotec). Plates were
centrifuged (400 g, 5min), supernatants discarded and cells
resuspended in FACS buffer. For flow cytometric analysis
after MCAO, brain cell suspensions were added to a 96-well
plate and stained with anti-mouse CD45-PE-Cy (clone 30-
F11, 1 µg/ml, BioLegend), anti-mouse Ly6C-PerCP-Cy5.5 (clone
HK1.4, 1 µg/ml, BioLegend) and anti-mouse TREM1-Alexa
Fluor 647 (clone L5-B8.2A12.3A12, 5 µg/ml, Abd Serotec)
following the above procedure. Data were acquired using a
LSR Fortessa (BD Biosciences) and analyzed using Summit
(Dako) or FlowJo software. Compensation was performed using
single-labeled samples as references and positive regions of
staining were defined based on unstained and/or isotype-stained
controls.
Experimental Design and Statistical
Analysis
Data from BV2 and adult mouse microglial are representative
of at least three independent experiments each containing a
minimum of triplicate technical replicates. Data from MCAO (n
= 6 mice per group) and intracerebral inflammation models (n
= 6 mice per group) are from a single experiment containing
independent biological replicates (i.e., mice). One sample t-
test was used to assess effects of microglial stimulation, MCAO
or intracerebral inflammation on Trem1 and Trem2 expression
by qPCR using the reference value of 1 for the PBS or sham
control groups. One-way ANOVA with Bonferroni correction
was used to assess effects of microglial stimulation on TREM2
protein expression by flow cytometry. Effects of IKK inhibition
on Trem1 and Trem2 expression were assessed using one-way
ANOVA with Dunnett’s correction (LPS + DMSO as reference
group). Effects of MCAO on microglial TREM1 expression
after MCAO measured by flow cytometry were assessed using
unpaired Student’s t-test. Analysis was performed blinded to
experimental treatment. Data were analyzed using GraphPad
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Prism and show mean ± SEM unless stated otherwise. P ≤ 0.05
was considered statistically significant.
RESULTS
Steady-State Microglial Trem family
Expression
To gain an initial understanding of steady-state microglial
expression of Trem family members we first examined the
pattern of gene expression in purified adult mouse microglia.
Trem2 expression was abundant in microglia from all forebrain
regions examined and at markedly greater levels than Trem1
and Trem3, both of which were expressed at negligible levels
(Figure 1A). Comparison to established genes highly expressed
in microglia (e.g., Csf1r, Cx3cr1, Itgam, Tmem119) gave an
indication of the extent of microglial Trem2 expression levels
(Figure 1B). To assess if microglia are the predominant cellular
source of Trem2 expression in the brain, we compared expression
in purified microglia and mixed brain cell lysates. Expression
was substantially enriched in purified microglia and negligible
expression was observed in mixed cell lysates (Figure 1C) thus
showing that microglia are the predominant source of Trem2
expression in the steady-state young adult brain. There is no
functional ortholog of Trem3 in humans where it is a pseudogene
(TREM3 has similar actions to TREM1 in mice; Chung et al.,
2002; Colonna, 2003) therefore we limited analysis in the
remainder of the study to Trem1 and Trem2.
Polarization of Mouse and Human
Microglia Differentially Regulates Trem
Expression
Next we examined the effect of in vitro activation of purified adult
microglia on Trem expression. We chose lipopolysaccharide
(LPS) and interleukin (IL)-4 as stimuli to induce contrasting
states of activation. Marked induction of Nos2 expression in
response to LPS and Arg1 expression in response to IL-
4 validated that purified adult microglia could be polarized
in the expected manner (Figure 2A). Trem1 expression was
significantly increased (∼10-fold) in response to LPS but
was unaffected by IL-4 stimulation (Figure 2A). In contrast,
Trem2 expression was suppressed by ∼90% in response to LPS
stimulation. Similarly toTrem1 expression,Trem2was unaffected
by IL-4 stimulation (Figure 2A). A similar pattern of responses
of Trem1 and Trem2 to LPS and IL-4 stimulation were observed
in the murine BV2 microglial cell line (Figure 2B), although we
note the generally more responsive nature of the isolated adult
microglia. These data indicate opposing regulation of Trem1 and
Trem2 genes by LPS-induced microglial activation and more
generally that the conditions under which microglia become
activated differentially affect Trem responses.
We next tested if the pattern of TREM regulation was also
observed in freshly isolated adult human microglia. Human
microglia were activated using comparable stimulation protocols
to mouse microglia that were previously validated (Durafourt
et al., 2013). As in mouse microglia, we found that TREM1
expression was significantly increased and TREM2 expression
significantly decreased in response to combined stimulation
with LPS and interferon-γ (IFNγ) whereas there were no
changes in response to combined IL-4 and IL-13 stimulation
(Figures 3A,B).
Differential Effects of Microglial
Polarization on TREM2 Protein Expression
Given the marked suppression of Trem2 gene expression by LPS
stimulation, we assessed if this effect extended to altered protein
expression. Previous studies have shown that TREM2 protein
is predominantly localized within intracellular vesicles of non-
activated microglial cell lines (Sessa et al., 2004; Prada et al.,
2006). Consistent with these data, using flow cytometry staining
of non-permeabilised cells we found that only a small proportion
(3–6%) of freshly isolated adult mouse microglia (Figure 4A) or
cultured BV2 cells (Figure 4B) stained positively for TREM2.
Stimulation with LPS or IL-4 increased the intensity of surface
F4/80 expression (Figure 4B) confirming cells were activated as
expected. LPS stimulation caused a significant reduction in the
proportion of surface TREM2+ microglia whereas expression
was unaffected in response to IL-4 (Figure 4C). Thus, the
differential effects of microglial polarization on Trem2 gene
expression are also evident at the protein level.
NF-κB Is a Common Mediator of Divergent
Microglial Trem1 and Trem2 expression
We next explored the intracellular signaling mechanisms
mediating the effect of LPS-induced microglial activation on
Trem2 expression. In view of the comparable responses of
BV2 cells to freshly isolated adult human and mouse microglia
observed above and the difficulties in acquiring large yields of
fresh cells we limited the following experiments to BV2 cells.
We focused on key components of the TLR signaling cascade
activated in response to LPS stimulation. Initial screening using
selective inhibitors of p38 MAPK, ERK1/2 kinase (MEK1/2),
JNK, and PI3 kinase showed no impact on LPS-induced Trem2
alterations (Figure 5A). In contrast, inhibition of the NF-
κB pathway using the highly selective IKK inhibitor BMS-
345541 (Burke et al., 2003) markedly attenuated the LPS-
stimulated suppression of Trem2 (Figure 5A). We found that
LPS stimulation suppressed Trem2 expression at 24 h and at
6 h but not 2 h after stimulation (Figure 5B). There was a
concentration-dependent attenuation of the suppressive effects
of LPS stimulation on Trem2 expression at 6 h and 24 h with
the higher concentration (10 µM) of BMS-345541 restoring
expression to near baseline levels. We also determined if
there was an important contribution of the NF-κB pathway to
microglial Trem1 regulation. IKK inhibition blocked the LPS-
induced increase in Trem1 expression 2 h after stimulation in a
concentration-dependent manner and this effect was sustained
to 6 and 24 h after LPS stimulation (Figure 5C). At 2 and 6 h, the
high concentration (10 µM) of BMS-345541 almost completely
inhibited the induction of Trem1. We also observed a potent
concentration-dependent effect of IKK inhibition on blocking
LPS-induced Nos2 expression (Figure 5D). These data show
that the NF-kB pathway is a common regulatory mechanism
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FIGURE 1 | Steady-state expression of Trem family genes in microglia. (A) Microarray expression intensities of Trem family genes in freshly isolated adult
murine microglia extracted from different forebrain regions. (B) Microarray expression intensities of Trem2 in isolated microglia and mixed cell brain homogenates from
different forebrain regions. (C) Microarray expression intensities of Trem2 relative to other established genes highly expressed in microglia. Microarray data were
re-analyzed from publicly available datasets (GSE62420) we generated previously (Grabert et al., 2016). Ctx, cerebral cortex; Hpp, hippocampus; Str, striatum.
underlying the divergent effects of microglial activation onTrem1
and Trem2 expression.
Microglial Trem1 and Trem2 Regulation
Have Contrasting TLR Sensitivity Profiles
LPS triggers intracellular signaling in microglia through binding
to the TLR4 receptor. We next determined if Trem expression
was affected in a similar manner when other TLRs were engaged.
Pam3CSK, poly (I:C), LPS, and CpG oligodeoxynucleotide
(CpG ODN) were used to stimulate TLR2/1, TLR3, TLR4,
or TLR9 respectively. Induction of Nos2 by all ligands
confirmed biological activity and responsiveness of microglia to
each stimulus (Figure 6A). Trem2 expression was significantly
suppressed by all TLR ligands although the magnitude varied
(Figure 6B). Expression of Trem2 was reduced to the greatest
extent by LPS (∼80%) and weakest suppression occurred in
response to poly (I:C) (∼35%) with intermediate effects induced
by Pam3CSK and CpGODN. In contrast to the largely consistent
suppression of Trem2 expression by activation of different TLRs,
Trem1 expression was affected in a TLR-specific manner. LPS, as
observed above, and poly (I:C) both induced a significant increase
in Trem1 expression whereas there was no effect of Pam3CSK
or CpG ODN (Figure 6C). These data show differences in the
regulation of Trem1 and Trem2 dependent on the specific TLR
engaged and suggestive of differences in the involvement of
signaling intermediates upstream of NF-κB (see Discussion).
Acute Brain Inflammation Induces
Divergent Changes in Trem Expression
In vivo
To test if the divergent regulation of Trem expression described
above in vitro was also evident in vivo, we used two models
of acute brain inflammation. First, the expression of Trem1
and Trem2 was determined in brain cell extracts 24 h after
intracerebral LPS injection in mice, a model that induces
a localized intense inflammatory reaction. LPS induced a
significant increase in Trem1 expression and a contrasting
suppression of Trem2 expression (Figure 7A) thus matching
the profile observed in vitro. Our data on Trem2 expression
are consistent with a previous study reporting suppressed
Trem2 in response to intraperitoneal LPS injection (Zheng
et al., 2016). These changes in expression of Trems occurred
alongside marked induction of both Nos2 and Arg1 (Figure 7A).
We also determined the effects of acute focal transient
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FIGURE 2 | Effects of polarized activation of murine microglia on Trem1 and Trem2 expression. (A) Microglia were extracted from the adult mouse brain then
cultured and stimulated for 24 h with lipopolysaccharide (LPS) or (IL-4) and gene expression measured by qPCR. (B) BV2 microglia were cultured and stimulated for
24 h with LPS or IL-4 and gene expression measured by qPCR. Data show mean ± SEM and are representative of three independent cultures each performed in
triplicate. Data are expressed as fold-change in expression vs. PBS treatment (dashed red line). *P < 0.05, one-sample t-test. LPS, lipopolysaccharide; IL-4,
interleukin-4.
FIGURE 3 | Effects of polarized activation of human microglia on
Trem1 and Trem2 expression. Microglia were extracted from resected
human brain samples then cultured and stimulated for 48 h with
lipopolysaccharide (LPS) and interferon-γ in combination or interleukin-4 (IL-4)
and IL-13 in combination. Expression of (A) TREM1 and (B) TREM2 were
measured by microarray. Data are displayed as log2 values and show mean ±
SD. *P < 0.05, ***P < 0.001 one-way ANOVA with Dunnett’s correction. LPS,
lipopolysaccharide; IFNγ, interferon-γ; IL-13, interleukin-13; IL-4, interleukin-4.
cerebral ischaemia induced by MCAO, a model causing a
prominent inflammatory response and microglial reactivity.
Trem1 expression was markedly increased and Trem2 expression
significantly suppressed in ipsilateral brain homogenates 24 h
after induction of MCAO (Figure 7B). In addition to microglial
reactivity, bone marrow-derived myeloid cells, which can express
Trem1, infiltrate the brain after acute cerebral ischaemia.
Therefore, to assess induction specifically in microglia in this
model, we used flow cytometry to selectively identify microglia
using their characteristic CD11b+CD45loLy6C− expression
profile and measured TREM1 expression intensity on this
population (Figure 7C). Expression of TREM1 was significantly
increased on microglia in MCAO compared to sham-operated
mice confirming induction of microglial TREM1 in vivo.
DISCUSSION
Our findings in the present study provide new insight to
the regulation of TREM family expression in microglia. Key
findings include (1) the divergent regulation of the major TREM
family receptors, TREM1 and TREM2, under neuroinflammatory
conditions in vitro and in vivo, (2) the common role for NF-κB in
controlling the divergent responses, and (3) that in the context of
TLR stimulation, the regulatory profile varies according to TLR
isoform.
We found marked differences in microglial gene expression
of the different Trem receptors in the steady-state mouse brain.
Expression of Trem2 was abundant (as indicated relative to
established highly expressed microglial genes) in all forebrain
regions examined in contrast to Trem1 and Trem3. This
pattern may reflect the involvement of TREM2 in homeostatic
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FIGURE 4 | Effects of polarized activation of murine microglia on TREM2 protein expression. (A) Microglia were identified as CD11b+CD45lo cells from
murine brain cell suspensions prepared from different brain regions and surface TREM2 expression measured by flow cytometry. Data show proportion of microglia
positive for TREM2 immunolabeling. (B) BV2 cells were stimulated with LPS or IL-4 for 24 h and cell surface TREM2 and F4/80 expression measured by flow
cytometry. Plots are representative of four independent cultures. (C) Quantification of cell surface TREM2 expression in BV2 cells stimulated with LPS or IL-4 for 24 h
by flow cytometry. Data show mean ± SEM and are representative of four independent cultures each performed in triplicate. **P < 0.01 one-way ANOVA with
Dunnett’s correction. LPS, lipopolysaccharide; IL-4, interleukin-4.
microglial function such that expression and signaling through
the TREM2 pathway are important constitutively for normal
microglial function. Indeed, the discovery of mutations in
TREM2 that impair basic microglial physiological activities
such as phagocytosis support the critical role for TREM2 for
homeostatic function (Takahashi et al., 2005; Kleinberger et al.,
2014). In contrast, TREM1 and TREM3 (mouse only), may
play more prominent roles when induced under inflammatory
conditions as amplifiers of cytokine responses (Sharif and Knapp,
2008) therefore negligible expression in steady-state microglia
is consistent with their quiescent inflammatory phenotype.
Our data showed that Trem2 expression was highly enriched
in purified microglia compared to brain homogenates which
supports microglia as the predominant and possibly sole cellular
source of Trem2 in the CNS. Although previous studies have
shown immunoreactivity for TREM2 protein on other cells
(Giuseppina et al., 2004; Guerreiro et al., 2013b) it is possible this
could reflect detection of the soluble ectodomain fragment bound
to ligand.
The expression profiles of both Trem1 and Trem2 in response
to stimulation were similar in all in vitro systems used and
showed marked alterations to LPS but not IL-4 (with or without
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FIGURE 5 | Effects of NF-κB inhibition on Trem1 and Trem2 expression in activated murine microglia. (A) BV2 cells were stimulated with LPS for 24 h with
or without co-incubation with inhibitors of IκB kinase (BMS-345541), PI3 kinase (LY294002), ERK1/2 kinase (MEK1/2) (PD98059), p38 MAP kinase (SB203580), or
c-Jun N-terminal kinase (SP600125) and expression of Trem2 measured by qPCR. (B-D) BV2 cells were stimulated for indicated duration with LPS with or without
co-incubation with the IkB kinase inhibitor (IKKi) BMS-345541 and (B) Trem2, (C) Trem1, and (D) Nos2 measured by qPCR. Data show mean ± SEM and are
representative of two (A) or four (B–D) independent cultures each performed in triplicate. Data are expressed as fold-change in expression vs. PBS treatment.
*P < 0.05, **P < 0.01, ***P < 0.001 one-way ANOVA with Dunnett’s correction. LPS, lipopolysaccharide; IKKi, IκB kinase inhibitor.
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FIGURE 6 | Effects of Toll-like receptor subtype stimulation on Trem1 and Trem2 expression in murine microglia. BV2 cells were stimulated with indicated
ligands for 24 h and expression of (A) Nos2, (B) Trem2, and (C) Trem1 measured by qPCR. Data show mean ± SEM and are representative of four independent
cultures each performed in triplicate. Data are expressed as fold-change in expression vs. PBS treatment (dashed red line). *P < 0.05, one-sample t-test. LPS,
lipopolysaccharide; poly I:C, polyinosinic-polycytidylic acid, CpG ODN, CpG oligodeoxynucleotide.
IL-13) stimulation. IL-4, a key mediator of alternative activation,
caused marked induction of the archetypal marker Arg1
indicating cells were generally responsive to IL-4. A previous
study showed induction of TREM2 protein by IL-4 stimulation
in peritoneal macrophages (Turnbull et al., 2006) suggesting that
there could be differences in TREM2 regulation in microglia
and macrophages. Nonetheless, we also do not exclude that IL-
4 in combination with other ligands in vitro or in vivo might
drive TREM2 expression. The contrasting induction of Trem1
and suppression of Trem2 in response to LPS challenge was
striking and is comparable with the profiles described in myeloid
cells outside the brain, including macrophages and dendritic cells
(Bouchon et al., 2000; Turnbull et al., 2006; Ito and Hamerman,
2012). We also observed similar expression responses in two in
vivo models of CNS inflammation, intracerebral LPS injection
and focal cerebral ischaemia induced byMCAO. The comparable
in vivo responses to LPS challenge and MCAO are interesting
but not surprising given that sterile inflammation induced
by ischaemic hypoxia and cell death trigger the release of
damage-associated molecular patterns (DAMPs) or “alarmins”
that activate similar receptors to microbial-derived ligands,
including TLRs (Rock et al., 2010). TREM1 amplifies TLR-
induced cytokine responses and its expression is induced in
response to a number of infectious stimuli (Bouchon et al.,
2001; Netea et al., 2006; Ornatowska et al., 2007; Hommes et al.,
2014). In contrast, TREM2 deficiency in macrophages caused
aggravated cytokine responses (Hamerman et al., 2006; Turnbull
et al., 2006). Thus, the responses of Trem1 and Trem2 we show
in vitro and in vivo highlight the possibility of co-ordinated but
divergent regulation of their expression as a potent mechanism
to tune the strength of microglial inflammatory responses.
Moreover, the potent suppression of Trem2 suggests certain
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FIGURE 7 | Trem1 and Trem2 expression in vivo in response to acute cerebral inflammatory challenges. (A) Mice were challenged with LPS by intracerebral
injection and expression of indicated genes measured in brain cell suspensions 24 h after challenge by qPCR. Data are expressed as fold-change in expression vs.
PBS treatment. Data show mean ± SEM. *P < 0.05, one-sample t-test, n = 6 per group (B) Transient focal cerebral ischaemia was induced in mice by middle
cerebral artery occlusion (MCAO) and Trem1 and Trem2 expression measured in brain homogenates ipsilateral to occlusion 24 h after MCAO. Data are expressed as
fold-change in expression vs. PBS treatment. Data show mean ± SEM. *P < 0.05, one-sample t-test, n = 6 per group (C) Brain cell suspensions were prepared 24 h
after MCAO and microglia identified by CD11b+CD45loLy6G−Ly6C− expression. TREM1 cell surface expression was measured on microglia by flow cytometry. Flow
cytometry plots are representative of six independent samples. Data show mean ± SEM. **P < 0.01, Student’s t-test, n = 6 per group.
acute inflammatory or injurious conditions in the CNS could
impair TREM2-dependent microglial physiological functions.
We restricted our analysis to <48 h after challenge, thus the
extent to which changes we report are sustained or reversible
are unknown (our unpublished data suggests normalization of
expression does occur for both Trem1 and Trem2 several days
later).
The signaling mechanisms underlying the regulation of
microglial TREM expression and whether these mechansims
share common elements is not well understood. Here we show
that NF-κB is a common transcriptional regulator involved
in LPS-induced microglial alterations to both Trem1 and
Trem2 supporting the co-ordinated nature of their divergent
responses. Consistent with this effect on Trem1 expression, the
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Trem1 promoter contains consensus binding sites for NF-κB
among other inflammation-induced transcription factors and in
macrophages NF-κB was shown to bind to the Trem1 promoter
(Zeng et al., 2007). The rapid and potent induction of Trem1
we observed after LPS challenge or ischaemia is consistent with
the well-established and rapid activation of NF-κB that can
occur within 5 min of stimulation (Lei et al., 2014). In contrast,
the Trem2 promoter does not contain NF-κB consensus sites
and given the normal role of NF-κB is to increase the rate of
transcription it is unlikely a direct interaction between NF-κB
and Trem2 mediates the suppressive effects of LPS or cerebral
ischaemia. A possible mechanism could be through NF-κB-
induced micro RNAs (miRNAs) that can negatively regulate
gene expression through binding the 3′ untranslated region
(UTR) of target genes and inducing mRNA degradation or
inhibiting translation (Valencia-Sanchez et al., 2006). Recent
studies have identified miRNA-34a as an NF-κB-inducible
miRNA upregulated in the diseased brain and this induction
correlated with suppressed TREM2 expression (Alexandrov et al.,
2013; Zhao et al., 2013). Further work showed that miRNA-34a
could interact directly with the 3’ UTR of the TREM2 mRNA
(Bhattacharjee et al., 2016).We noted that the induction ofTrem1
in vitro occurred as early as 2 h after LPS stimulation whereas the
suppression of Trem2 was not observed until 6 h. These kinetics
are consistent with a rapid and direct transcriptional regulation
of Trem1 and a suppressive mechanism on Trem2 involving
an intermediate such as a miRNA and subsequent mRNA
degradation. Our data demonstrating the non-uniform effects
of stimulating different TLR subtypes on microglial Trem1 and
Trem2 provides further insight to their regulation. Of particular
note is that Trem1 was induced only by ligands (LPS and poly
I:C) that activate TLRs capable of signaling via the MYD88-
independent TRIF module (i.e., TLR3 and TLR4) (O’Neill et al.,
2013). In contrast, Trem2 was suppressed by ligands activating
all TLRs we tested including those that can signal via MYD88
only (TLR2/1, TLR9), MYD88 and TRIF (TLR4) or TRIF only
(TLR3) although suppressive effects were weakest for TLR3.
Both the MYD88 and TRIF pathways can activate NF-κB thus
in agreement with the common effects of NF-κB pathway
inhibition we found. However, the TLR sensitivity profiles
suggest possible differences for Trem1 and Trem2 regulation
in signaling upstream of NF-κB. Induction of Trem1 appears
to be dependent on the MYD88-independent TRIF pathway
whereas suppression of Trem2 could involve either MYD88
or TRIF modules, although further work targeting individual
subcomponents of TLR signaling is needed to definitively assess
this. Given the interest in immunomodulatory therapeutics
targeting TLR signaling (Parker et al., 2005), it may be important
to consider that effects on relative Trem1 and Trem2 expression
could be variable depending on the specific elements of TLR
signaling targeted.
TREM2 mutations have been associated with several
neurodegenerative diseases (Colonna and Wang, 2016) and
TREM1 variants with cognitive decline and Alzheimer-related
amyloid pathology (Replogle et al., 2015). Most, although not
all, TREM2 mutations appear to be loss-of-function raising the
possibility of augmenting activity in the TREM2 pathway (e.g.,
via synthetic ligands or activating antibodies) as a potential
therapeutic strategy in certain circumstances. Indeed, lentiviral
overexpression of TREM2 reduced pathology and improved
cognitive performance in a mouse model of AD-like amyloidosis
(Jiang et al., 2014). However, the efficacy of pharmacological
approaches may depend on the availability of the transmembrane
receptor, which will be influenced by transcriptional regulation
among other factors. Although our present study was limited
to acute neuroinflammatory conditions, our data nonetheless
highlight the importance of understanding how themore chronic
neuroinflammatory environment in the aging and degenerating
brain might influence TREM expression. It is pertinent to
note that TREM2 expression was reduced in hippocampus
from AD patients compared to controls (Zhao et al., 2013),
although increased TREM2 expression has also been shown in
AD-like mouse models and models of demyelinating disease
(Piccio et al., 2007; Cantoni et al., 2015; Jay et al., 2015; Wang
et al., 2015). Thus, a clearer understanding of how TREM
expression is regulated in age-related neurological disease
will be needed to guide how best to apply TREM-targeted
interventions.
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